Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with HCV GT1 mono-infection and HIV/HCV coinfection (C-WORTHY): a randomised, open-label phase 2 trial

Publication Type:

Journal Article

Source:

Lancet, Volume 285, Issue 9973, p.1087-1097 (2015)
Top